Dr. Gordon Brown, DO, FACOS
Associate Clinical Professor, Rowan University School of Osteopathic Medicine
Doctor of Osteopathic Medicine, Rowan University School of Osteopathic Medicine
Dr. Gordon A. Brown has 16 years of experience in Urology. He earned his BA in Cell and Molecular Biology from Boston University and his DO from Rowan University School of Osteopathic Medicine. He completed two residencies in General Surgery and Urology at the Rowan University School of Osteopathic Medicine and a fellowship in Urologic Oncology at the University of Texas MD Anderson Cancer Center. Currently, he serves as a Physician and Director of the Center for Advanced Therapeutics at New Jersey Urology and as Program Director of Urologic Surgery Residency at Rowan University School of Osteopathic Medicine.
g********@n*****.com
(856) ***-****
Voorhees, New Jersey
Comprehensive data on expert witnesses: Access detailed litigation history and performance metrics.
Swift assessment: Quickly evaluate an expert's track record.
Informed decisions: Make better choices when selecting or challenging expert witnesses in any case.
Expert Witness Activity
Plaintiff Cases
Defense Cases
Expert Challenges
Deposition Transcripts
Publications
68
Media & News
373
Social Media Mentions
Expert Institute operates independently and objectively as an expert witness data provider. Expert Institute does not employ, endorse, or have an affiliation with any expert witnesses for which data is provided.
Case Name | Role | Filed Date |
---|
Defense
Plaintiff
0
25
50
75
100
2000
0
2002
0
2004
0
2006
0
2008
0
2010
0
0
25
50
75
100
Radar found 68 records
Title | Type |
---|---|
The Impact of a Biopsy Based 17-Gene Genomic Prostate Score on Treatment Recommendations in Men with Newly Diagnosed Clinically Prostate Cancer Who are Candidates for Active Surveillance | Journal Article |
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS) | Journal Article |
Primary aortoesophageal fistula | Journal Article |
Radar monitors a wide array of publication sources, including links to abstracts.
Review book chapters, journal articles, research papers, trade publications, technical reports, conference proceedings, and more.
Radar found 373 records
Title | Description |
---|---|
Key Takeaways on the Evolving NMIBC Treatment ... | Jul 1, 2024 ----- The potential role for IsoPSA in prostate cancer risk assessment Urology Times staff June 23rd 2024. Article ... investigation in the phase 3 ... |
Does Body Mass Index (BMI) Matter? - Beyond the Abstract | May 20, 2024 ----- Department of Urology , Jefferson Health New Jersey, Stratford, NJ Texas College of Osteopathic Medicine , University of North Texas Health ... |
enGene to Present Details of its Pivotal Phase 1/2 ... | May 2, 2024 ----- Gordon Brown , Director of the Center for Advanced Therapeutics and Urologic Oncology , Summit Health-South, at 10:30 a.m. CT on Friday, May 3 rd ... |
Radar scours thousands of media and news sources across the internet 24/7.
Access interviews, webinars, TV appearances, blog posts, columns, whitepapers, PDFs, profressional profiles, and more.
Institution | Degree Type |
---|---|
Rowan University School of Osteopathic Medicine | Doctor of Osteopathic Medicine |
Boston University | Bachelor of Arts |
Title | Employer |
---|---|
Associate Clinical Professor | Rowan University School of Osteopathic Medicine |
Program Director | Rowan University School of Osteopathic Medicine |
Physician | New Jersey Urology |
Access detailed litigation history and performance metrics.
Access your Radar profile through Expert iQ, our secure, cloud-based platform that hosts AI-driven insights.
Delivered in 3-5 days
Receive your profile swiftly, with Radar gathering intelligence from thousands of data points.
24/7 monitoring for 12 months
Stay informed with continuous monitoring and live alerts, ensuring your profile is always up-to-date.